TITLE

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

AUTHOR(S)
Derom, E Y; Pauwels, R A
PUB. DATE
January 1992
SOURCE
Thorax;Jan1992, Vol. 47 Issue 1, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66040273

 

Related Articles

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma: Commentary. Rees, P. John // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    Focuses on the control of asthma by inhaled long acting beta agonists and corticosteroids. Effectiveness of the combination of fluticasone/salmeterol and budesonide/formoterol; Dose response of corticosteroids and formoterol; Onset of bronchodilation.

  • Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma. Bartow, R.A.; Brogden, R.N. // Drugs;Feb1998, Vol. 55 Issue 2, p303 

    Formoterol, a selective β2-adrenoceptor agonist, produces effective dose-proportional bronchodilation, which persists for up to 12 hours, in patients with reversible obstructive respiratory disease. Bronchodilation is significant within minutes of inhalation, maximal within 2 hours, and at...

  • Pharmacotherapy -- add-on therapies.  // CMAJ: Canadian Medical Association Journal;9/13/2005 Supplement, Vol. 173, pS37 

    The article focuses on the effectiveness regarding the use inhaled corticosteriods (ICS)and leukotriene receptor antagonists (LTRA)as add-on therapy in treating children with asthma. The effectiveness ICS has been compared with long-acting bronchodilators (LABA) such as salmenterol or...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Bronchodilator Combination Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Sethi, Sanjay // Current Clinical Pharmacology;Feb2011, Vol. 6 Issue 1, p48 

    Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, and its prevalence is rising worldwide. Bronchodilators remain the cornerstone of COPD treatment, especially inhaled �2-adrenergic receptor agonists and inhaled anticholinergics. Long-acting...

  • Efficacy of indacaterol in the treatment of patients with COPD. Jones, Paul W.; Barnes, Neil; Vogelmeier, Claus; Lawrence, David; Kramer, Benjamin // Primary Care Respiratory Journal;Dec2011, Vol. 20 Issue 4, p380 

    Effective bronchodilation is an important part of the management of patients with chronic obstructive pulmonary disease (COPD) and can improve breathlessness and ability to undertake physical activities. Indacaterol is a new once-daily, long-acting inhaled bronchodilator for COPD. We review here...

  • Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Haney, Sarah; Hancox, Robert J. // Respiratory Research;2007, Vol. 8, p19 

    Background: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator response to moderate doses of inhaled short acting beta-agonists during acute bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or other bronchodilators is...

  • Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate. King, Paul T. // Clinical Medicine: Therapeutics;2009, Issue 1, p1321 

    Arformoterol tartrate is a newly developed long-acting ssβ2-agonist with both acute and prolonged bronchodilator effects. It is formed of 2 isomers (R,R/R,R) which distinguishes it from the more commonly used racemic formoterol (R,R/S,S). The active isomer is the (R,R) and in vitro...

  • A role of indacaterol in chronic obstructive pulmonary disease management: a turning point or crossroads? Feldman, Gregory J.; Edin, Anton // Journal of Thoracic Disease;Aug2013, Vol. 5 Issue 4, p378 

    The authors reflect on the use of indacaterol, an inhaled ultra-long acting 2-agonists, for the treatment of patients with stable but symptomatic chronic obstructive pulmonary disease (COPD). The authors state the approval of using indacaterol as the first effective once-daily long-acting...

  • Long-Acting β Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease. Cazzola, M.; Donner, C.F. // Drugs;Aug2000, Vol. 60 Issue 2, p307 

    Long-acting β agonist bronchodilators (e.g. formoterol, salmeterol) are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD). In the short term, both salmeterol and formoterol appear to be more effective than short-acting β agonists, and in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics